-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$16.50971.43% Upside
NGM Biopharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover NGM Biopharmaceuticals, Inc.?
NGM Biopharmaceuticals, Inc. has been rated by research analysts at Raymond James, Goldman Sachs in the past 90 days.